New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 23, 2014
08:56 EDTBIIBBiogen still sees FY CapEx approximately $300M
Believes TECFIDERA is on track to become the leading MS product in the U.S. Says outside the U.S., demand for TECFIDERA has been broad; launch trajectories similar to experience in U.S. Continues to be in discussions with AIFA to resolve its dispute on Tysabri for February 2009-January 2013. Says FY guidance "meaningfully increased" due primarily to the  growth  of  TECFIDERA in the U.S. and the EU., the strength of our other MS therapies and clarity on the AIFA pricing matter. Comments from slides that will be presented on the Q2 earnings conference call.
News For BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 27, 2015
15:35 EDTBIIBNotable companies reporting before tomorrow's open
Subscribe for More Information
15:26 EDTBIIBBiogen January weekly volatility elevated into Q4 and outlook
Subscribe for More Information
January 15, 2015
07:29 EDTBIIBOutlook for Biogen trials positive , says RBC Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use